20 Feb 2008 - Ablynx announced that it has received an undisclosed milestone payment from Novartis for an exclusive research license in one of the programmes that is a component of their ongoing Research and Development alliance. Novartis and Ablynx are collaborating to discover and develop therapeutic Nanobodies® for a range of disease areas, against a number of targets that are difficult to address with conventional antibodies and their fragments.
The alliance was entered into in December 2005, and extended in December 2007 for a further year. Under the terms of this ongoing agreement, Ablynx receives upfront fees, license fees and funding for research and development. In addition, Ablynx will be eligible for milestone payments and royalties upon commercialisation. Novartis has exclusive rights to develop and commercialise the Nanobody® products resulting from the collaboration. Financial terms are not disclosed.
 |
www.bionity.com/news/e/78308 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/78308 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |